206 related articles for article (PubMed ID: 14645194)
41. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
[TBL] [Abstract][Full Text] [Related]
42. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
43. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
[TBL] [Abstract][Full Text] [Related]
44. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
45. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
Yıldız GA; Şükür YE; Ateş C; Aytaç R
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
[TBL] [Abstract][Full Text] [Related]
46. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
[TBL] [Abstract][Full Text] [Related]
48. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
Younis JS; Izhaki I; Ben-Ami M
Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
[TBL] [Abstract][Full Text] [Related]
49. Elevated early follicular progesterone levels and in vitro fertilization outcomes: a prospective intervention study and meta-analysis.
Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
Fertil Steril; 2014 Aug; 102(2):448-454.e1. PubMed ID: 24929258
[TBL] [Abstract][Full Text] [Related]
50. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
51. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
52. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
53. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
[TBL] [Abstract][Full Text] [Related]
54. Progesterone change in the late follicular phase affects pregnancy rates both agonist and antagonist protocols in normoresponders: a case-controlled study in ICSI cycles.
Demir B; Kahyaoglu I; Guvenir A; Yerebasmaz N; Altinbas S; Dilbaz B; Dilbaz S; Mollamahmutoglu L
Gynecol Endocrinol; 2016; 32(5):361-5. PubMed ID: 26654315
[TBL] [Abstract][Full Text] [Related]
55. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
56. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
[TBL] [Abstract][Full Text] [Related]
57. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
58. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
59. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
[TBL] [Abstract][Full Text] [Related]
60. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles.
Kyrou D; Al-Azemi M; Papanikolaou EG; Donoso P; Tziomalos K; Devroey P; Fatemi HM
Eur J Obstet Gynecol Reprod Biol; 2012 Jun; 162(2):165-8. PubMed ID: 22425288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
